Skip to main content
OpenTrials
Completed

NCT Number: NCT05594953

Outcomes Using MARS for Patients With ALF

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alcoholic Hepatitis Acute Liver Failure Alcohol-Induced Disorders Alcohol-Related Disorders Chemically-Induced Disorders Digestive System Diseases Hepatic Insufficiency Hepatitis Hepatitis, Alcoholic Liver Diseases Liver Diseases, Alcoholic Liver Failure Liver Failure, Acute Substance-Related Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

Methodist Dallas Medical Center

Dallas, Texas, 75203, United States

About this study

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure
  • The patient underwent at least one round of dialysis using plasma exchange or MARSTM

Exclusion criteria

  • Patient not meeting the inclusion criteria will be excluded.

All patients who underwent MARS at MDMC will be included in the study population.

Treatment and study plan

Primary outcomes

  1. Transplant free survival mortality

    Time frame: Rate at 30 days

    transplant will be measured by date of death, and discharge

  2. Difference in Demographics

    Time frame: Rate at 30 days

    co-morbidities, etiology of liver failure between those treated with MARS vs. controls

  3. Improvement in Transplant

    Time frame: Rate at 30 days

    Determine whether treatment with MARS can help facilitate improvement in HE, LOS, and ICU duration.

Secondary outcomes

  1. Demographics

    Time frame: January 1, 2019 to January 31, 2022

    age (years), gender (male/female), race (Caucasian, black, Hispanic, Asian, other), BMI (kg/m2)

  2. Hepatorenal syndrome

    Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days

    Y/N

  3. Need for vasopressor support

    Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days

    Y/N

  4. Sepsis (as measured by by QSOFA criteria):

    Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days

    Y/N

  5. Need for CRRT as documented in the chart:

    Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days

    Y/N

  6. ICU duration

    Time frame: date of ICU admission and date of discharge (or death)

    days of date of ICU duration

  7. long term dialysis

    Time frame: (in hospital [date of death or discharge or transplant]) and at 30 days

    Need for long term dialysis (Y/N)

Sponsors and collaborators

Lead sponsor

Methodist Health System

Other

Registry information

Official study title

Outcomes Using MARS: A Single Center Experience

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Oct 26, 2022
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.